EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Mitral Annular Disjunction in Heritable Thoracic Aortic Disease: Insights From the Montalcino Aortic Consortium

Kishan L Asokan iD, Jennifer R Landes iD, Wannes Renders, Laura Muiño Mosquera iD, Julie De Backer iD, David W Jantzen, Anji T Yetman iD, Gisela Teixido-Tura iD, Arturo Evangelista, Richmond Jeremy iD, Edward G Jones iD, Shaine Morris iD und 8 weitere

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.124.036274 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Kishan L Asokan und 19 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Health Science Center at Houston TX. Hauptthemen laut MEDLINE: Mitral Valve Prolapse, Mitral Valve, Smad3 Protein, Mitral Valve Insufficiency. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mitral annular disjunction (MAD), posterior displacement of the mitral valve leaflet hinge point, predisposes to arrhythmias or sudden cardiac death. We evaluated the burden of MAD, mitral valve prolapse (MVP), and mitral regurgitation (MR) by heritable thoracic aortic disease gene in a cross‐sectional analysis of 2014–2023 data in the Montalcino Aortic Consortium registry. Methods and Results MAD was determined by direct measurement of echocardiographic images. MR and MVP were defined according to current clinical guidelines. Associations were evaluated using χ 2 or Fisher exact tests. MR and MVP were enriched in Montalcino Aortic Consortium participants (672) with pathogenic variants (PV) in transforming growth factor‐β pathway genes. The combination of MR and MVP was associated with mitral surgery and arrhythmias. In the subgroup with available images, MAD was enriched in SMAD3 PV compared with other transforming growth factor‐β PV (prevalence ratio 1.8 [1.1–2.8], P 10 mm) was only observed in the transforming growth factor‐β subgroup and was further enriched in participants with SMAD3 PV (prevalence ratio 3.1 [1.1–8.6]). MVP (prevalence ratio 5.2 [3.0–9.0]) and MR (PR 2.7 [1.8–3.9]) were increased in participants with MAD, but MAD was not independently associated with adverse cardiac or aortic events.

Conclusions

Pathological mitral valve phenotypes are more prevalent in individuals with PV in transforming growth factor‐β pathway genes, particularly SMAD3 . MR and MVP but not MAD are associated with adverse aortic and cardiac events. Because congenital mitral disease may be the primary presenting feature of SMAD3 PV, genetic testing for heritable thoracic aortic disease should be considered for such individuals, especially if they also have a family history of heritable thoracic aortic disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mitral Valve ProlapseMitral ValveSmad3 ProteinMitral Valve InsufficiencyHumansMaleFemaleMiddle AgedCross-Sectional StudiesRegistriesAortic Aneurysm, ThoracicAgedAdultEchocardiographyGenetic Predisposition to DiseaseAorta, ThoracicPhenotypeTransforming Growth Factor betaPrevalence

Stichwörter der Autor:innen

Loeys–Dietz syndromecardiovascular geneticscongenital heart diseasemitral valvethoracic aortic aneurysms and dissections

Substanzen

SMAD3 protein, humanSmad3 ProteinTransforming Growth Factor beta

Autor:innen und Institutionen

  • University of Texas Health Science Center at Houston TX.
  • Ghent University Hospital Ghent Belgium.
  • University of Nebraska Medical Center Omaha NE.
  • University Hospital Vall d'Hebron Barcelona Spain.
  • University of Sydney Australia.
  • Texas Children's Hospital Houston TX.

ORCID-Profile: Kishan L Asokan, Jennifer R Landes, Laura Muiño Mosquera, Julie De Backer, Anji T Yetman, Gisela Teixido-Tura, Richmond Jeremy, Edward G Jones, Shaine Morris, Tam Doan, Alan Braverman, Guillaume Jondeau, Olivier Milleron, Dianna M Milewicz, Siddharth K Prakash

Zitieren

APA

Asokan, K. L., Landes, J. R., Renders, W., Muiño Mosquera, L., De Backer, J., Jantzen, D. W., Yetman, A. T., Teixido-Tura, G., Evangelista, A., Jeremy, R., Jones, E. G., Morris, S., Doan, T., Ouzonian, M., Braverman, A., Jondeau, G., Milleron, O., Milewicz, D. M., Prakash, S. K., & Montalcino Aortic Consortium * (2024). Mitral Annular Disjunction in Heritable Thoracic Aortic Disease: Insights From the Montalcino Aortic Consortium. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.036274

Vancouver

Asokan KL, Landes JR, Renders W, Muiño Mosquera L, De Backer J, Jantzen DW, et al. Mitral Annular Disjunction in Heritable Thoracic Aortic Disease: Insights From the Montalcino Aortic Consortium. Journal of the American Heart Association. 2024. doi:10.1161/jaha.124.036274

BibTeX
@article{Asokan2024,
  author = {Asokan, Kishan L and Landes, Jennifer R and Renders, Wannes and Muiño Mosquera, Laura and De Backer, Julie and Jantzen, David W and Yetman, Anji T and Teixido-Tura, Gisela and Evangelista, Arturo and Jeremy, Richmond and Jones, Edward G and Morris, Shaine and Doan, Tam and Ouzonian, Maral and Braverman, Alan and Jondeau, Guillaume and Milleron, Olivier and Milewicz, Dianna M and Prakash, Siddharth K and Montalcino Aortic Consortium *, Montalcino Aortic Consortium *},
  title = {Mitral Annular Disjunction in Heritable Thoracic Aortic Disease: Insights From the Montalcino Aortic Consortium},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.124.036274}
}
Kostenlos starten →